NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf

CompletedN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Relapsing Multiple Sclerosis

Interventions: Ofatumumab, Ocrelizumab

Countries: United Arab Emirates

This is a retrospective and prospective, observational mixed-methods (quantitative and qualitative) cohort study of patients who are treated with either Ofatumumab or Ocrelizumab that will be recruited and followed up for one year to collect their profiles across the Gulf countries.

Eligibility overview

Sex: ALL

Age: 18 Years to 60 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Males and Females.
* Age 18 to 65 years.
* Confirmed RMS diagnosis as per the 2017 updated McDonald's criteria (Thompson et al., 2018).
* Having their first dose of either drugs during the index period (2019 onwards and up to 1 year since start of the active recruitment period).
* The decision to initiate either drug should be based on the patient's disease and taken by the treating physician before the decision of inviting the patient to participate in the study.
* The patient agreed and provided informed consent on the use of his/her de-identified data.

Exclusion Criteria:

* Patients below 18 years or above 65 years.
* Pregnant females.
* SPMS and/or PPMS patients.
* The patient's refusal to be included in the study.

Locations (6)

Al Ain Abu Dhabi, United Arab Emirates, United Arab Emirates
Sharjah city, United Arab Emirates, United Arab Emirates
Abu Dhabi, United Arab Emirates
Abu Dhabi, United Arab Emirates
Dubai, United Arab Emirates
Sharjah city, United Arab Emirates